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ABSTRACT
Unusual growth in pharma industry has provoked regulatory agencies to establish regulations regarding bioavailability (BA) and bioequivalence 
(BE) studies. The BA and BE testing are essential in drug development process, provides the information regarding the kinetics (area under the curve 
[AUC], Cmax, Tmax, λz, t½, AUC0→Tss, Cmaxss, Cminss, Cavgss, Tmaxss) of single and multiple dose studies and the comparison of medicinal products. Indian Council 
of Medical Research (ICMR), Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Indian National Science 
Academy (INSA), Institutional Animal Care and Use Committee Guidebook (IACUC), National Institutes of Health, Food and Drug Administration, 
World Health Organization (WHO) provides the informations for strengthening the ethical guidelines for using humans and animals in clinical trials 
globally. Experimental design will help for better selection of models, number of subjects/animals, study conditions, randomizations, selection of 
control groups. Statistical evaluation parameters like Analysis of Variance help for the better interpretation of the data. The present study was aimed 
to study the need for BA and BE studies, ethical guidelines, experimental designs, pharmacokinetic endpoints, and their statistical evaluations.
Keywords: Ethical guidelines, Study design, Bioavailability, Bioequivalence.
INTRODUCTION
Bioavailability (BA) and bioequivalence (BE) testing are essential in 
the drug development process because they create the foundation for 
regulatory decision making when evaluating formulation changes and 
lot-to-lot consistency in innovator products. They also serve as the 
primary components to demonstrate therapeutic equivalence between 
generic products and the reference innovator product [1]. The increasing 
number of drugs that can be obtained from different manufacturers and 
the phenomenal growth of the generic pharmaceutical industry have 
prompted regulatory agencies such as Food and Drug Administration 
(FDA) to establish BA and BE regulations put into effect in January 1977 [2]. 
BA studies are performed for both approved active drug ingredients [3,4] 
and therapeutic moieties not yet approved for marketing by the FDA. 
New formulations of active drug ingredients must be approved by the 
FDA before marketing [5]. In approving a drug product for marketing, 
the FDA ensures that the drug product is safe and effective for its labeled 
indications for use. Moreover, the drug product must meet all applicable 
standards of identity, strength, quality, and purity [6]. To ensure that 
these standards are met, the FDA requires BA/pharmacokinetic studies 
and, where necessary, BE studies for all drug products. For new drugs not 
fully approved for marketing, regulatory agencies require that in vivo BA 
studies should be performed on the dosage form proposed for marketing 
[7,8]. In vivo BA studies are also performed for new formulations of active 
drug ingredients or therapeutic moieties that have full NDA approval and 
are approved for marketing.
NEED FOR BA AND BE STUDIES
BA studies provides information regarding the pharmacokinetics of the 
new formulation, new dosage form such as fraction of drug absorbed, 
linearity, and non-linearity in the pharmacokinetics of the drug and the 
dose proportionality, performance of the formulation [9]. It helps to 
establish dosage regimen.
BE studies are performed for the comparison of two medicinal 
products containing the same active substance, two products marketed 
by different licenses containing the same active ingredients or for 
alternate therapy [10]. The post approval changes that include a change 
in the supplier of the active ingredient, a change in the formulation 
or a change in the manufacturing site, the manufacturer must assure 
that drug product performance did not change and is same for the 
change by conducting BE studies. The drug product performance 
may be determined in vivo by BE studies or in vitro by comparative 
drug release or dissolution profiles, the schematic flow is illustrated 
in Fig. 1. Comparative drug product performance is important in the 
development of generic drug product is shown in the Fig. 2.
ETHICAL GUIDELINES IN CLINICAL TRAILS
Ethics in clinical research focuses largely on identifying and 
implementing the acceptable conditions for exposure of some 
individuals to risks and burdens for the benefit of the society at 
large [11,12]. In 1964, the World Medical Association Declaration of 
Helsinki underscored 12 basic principles for the conduct of human 
biomedical research shown in Fig. 3 [13]. In India the ICMR, in February 
1980, released a “Policy Statement on Ethical Considerations involved 
in Research on Human Subjects.” In 1970s and 1980s, researchers at the 
Institute for Cytology and Preventive Oncology in New Delhi carried out 
a study on different stages of cervical dysplasia or precancerous lesions 
of the cervix [14]. These patients were left untreated and by the end of 
the study 71 women had developed malignancies and lesions in nine 
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Fig. 1: Drug product performance and new drug product 
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of them had progressed to invasive cancer. After the controversy about 
the study became public in 1997, the ICMR started developing “Ethical 
Guidelines for Biomedical Research on Human Subjects” and finalized 
them in the year 2000. Although not a law, these guidelines have been 
put into force through Schedule Y.
In the technical committee of CDSCO second meeting headed by 
drug controller general deciding that Institutional Ethics Committee 
would review and approve protocol of any clinical trial. Further, apex 
committee recommending that the present practice of review and 
approval of BA/BE study protocols by Independent Ethics Committees 
should be discontinued. Later the committee decided that Independent 
Ethics Committee should be allowed to review and approve only 
protocols for BA/BE studies of approved drug molecules [15]. 
Institutional Ethics Committee Registration is approved by CDSCO 
as per newly introduced rule 122D. Requirements for registration 
of Institutional Ethics Committee is as per the provisions mentioned 
under appendix VII of schedule Y.
CPCSEA [16], INSA [17], Institutional Animal Care and Use Committee 
Guidebook (IACUC) [18] provides information for laboratory animal 
facility and general principles in animal research illustrated in Fig. 4.
FDA provides information regarding protection of human subjects 
(21CFR50) [19], standards for institutional review boards for clinical 
trials (21CFR16 and 56) [20], guidance for industry product development 
under the animal rule [21], approval for new drugs when human efficacy 
studies are not ethical or feasible (21CFR314) [22]. World Health 
Organization provides information for international ethical guidelines 
for biomedical research involving human subjects [23].
IMPORTANT STEPS IN CONDUCTING EXPERIMENTAL DESIGNS (IN 
CASE OF ANIMALS)
Selection of animal models [24-27]
Spontaneous models
Spontaneous animal models are those that exist in the nature with 
similarity to human condition or disease. For example occurrence of 
natural killer cells in rats is good example.
Experimental models
Experimental models are those that need to be created to attend the 
conditions we desired to be tested. Surgical models are examples of 
experimental or induced models.
Genetically modified models
Molecular biology has permitted modifying the animal genome to attain 
the aims of some studies. Genetically, modified models are therefore 
created for that reason. Introduction of an alien DNA and the knock-out 
models are good examples of these animal models.
Negative models
Negative models thus include animals that exhibit a lack of reactivity 
to a particular stimulus. Their main application is in studies on the 
mechanism of resistance that seek to gain close into its physiological 
basis. Why dogs do not develop arteriosclerosis is one of this questions 
that may be answered by a negative model.
Orphan models
Contrarily, an orphan model is used to investigate either a condition 
or disease that occurs in some species but not in humans. It may be 
important to identify diseases that may affect humans in the next 
future. The mad-cow disease is an example.
Number of animals to be selected [28,29]
Power analysis is most common used. The formulae are complex 
however statistical packages offer power analysis of which mostly 
used are SAS, SPSS, Epi-6, statistical. Calculations can be easily done 
by several online internet sites like http//:www.biomath.info; http//
www.stat.iowa.edu/~rlenth/Power//index. The number of animals 
that can be grouped in standard cages is a practical consideration for 
determining experimental group size.
Randomization [30,31]
Allocation of animals to different groups should be at random. 
Randomization avoids bias and guarantee that groups have same 
probability to receive treatment. Some of the methods are dices, 
envelopes containing pieces of papers with codes.
Control groups [32]
Positive controls
In positive control groups, changes are expected. The positive control 
acts as a standard against which to measure difference in severity 
between experimental groups. An example of a positive control is a toxin 
administered to an animal, which results in reproducible physiological 
changes or lesions.
Fig. 2: Drug product performance and generic drug product 
development
Fig. 3: Ethical guidelines for using humans in clinical trials
Fig. 4: Ethical guidelines for using animals in clinical trials
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Negative controls
Negative controls are expected to produce no change from the normal 
state. In the example above, the negative control would consist of 
animals not treated with the toxin. The purpose of the negative control 
is to ensure that an unknown variable is not adversely affecting the 
animals in the experiment, which might result in a false-positive 
conclusion.
Sham controls
A sham control is used to mimic a procedure or treatment without the 
actual use of the procedure or test substance. A placebo is an example 
of a sham control used in pharmaceutical studies.
Vehicle controls
A vehicle control is used in studies in which a substance for example 
saline or mineral oil is used as a vehicle for a solution of the 
experimental compound. In a vehicle control innocuous substance is 
used alone, administered in the same manner, in which it will be used 
with the experimental compound. When compared with the untreated 
control, the vehicle control will determine whether the vehicle alone 
causes any effects.
Comparative control
A comparative control is often a positive control with a known 
treatment that is used for a direct comparison to a different treatment. 
For example, when evaluating a new chemo preventive drug regime 
in an animal model of cancer, one would want to compare this regime 
to the chemo preventive drug regime currently considered “accepted 
practice” to determine whether the new regime improves cancer 
prevention in that model.
IMPORTANT STEPS IN CONDUCTING EXPERIMENTAL DESIGNS (IN 
CASE OF HUMAN BEINGS)
Healthy subject versus patients
Healthy subjects are preferred over patients. Practical advantages 
associated with enrolling healthy subjects include simpler inclusion 
and exclusion criteria, easier recruitment, homogenous population 
characteristics and less use of concomitant medications. In addition, 
healthy volunteers are also generally more amenable to intensive 
pharmacokinetic sampling schedules. A major statistical argument 
in favor of using healthy subjects in BE testing is that the effects of 
formulation factors can be readily evaluated rather than the effects 
of inter-or-intra subject factors that are known to affect the drug 
absorption, disposition or both [33].
Selection of subjects
Healthy volunteers should be used in BA studies. Healthiness is 
ascertained by vital signs such as temperature, pulse, respiration, blood 
pressure, and laboratory tests on blood, urine and also by liver function 
tests such as serum alkaline phosphate.
Eligibility criteria
Age, sex and body weight also influence the blood level profile of a drug 
product. In general 18-year-old, male subjects act as volunteers in the 
study [34]. It is difficult to obtain a sufficient number of subjects with 
this specification and hence acceptable normal ranges are 18-60 years 
of age and 120-200 lb of body weight. Males are preferred over females 
because menstrual cycle, pregnancy, lactation, and menopause stages 
that occur in females may affect the blood level profiles of the drug. 
Medical history of the subjects has to be reviewed critically by a panel 
of experts.
Number of subjects
For a sensible BE study the sponsor should enroll a number of subjects 
sufficient to ensure adequate statistical results, which is based on the 
power function of the parametric statistical test procedure applied. The 
number of subjects should not be <12 (sometimes more than 24 are 
needed as in case of highly variable drug). In most of the cases 18-24 
normal healthy subjects preferably non-smoking are selected [35,36].
Randomization [30,31]
The selected subjects should be distributed randomly to different 
groups to achieve a uniform distribution of the available volunteers 
with respect to age, sex, and body weight and to avoid bias.
Study conditions
The selected subjects should be maintained on a uniform diet and none 
of them should have taken any drug at least 1 week prior to the study.
Fasting and fed state considerations
In general, a single dose study should be conducted after an overnight 
fast at least 10 hrs, with subsequent fast of 4 hrs following dosing. For 
multiple dose fasting state studies, when an evening dose must be given, 
2 hrs of fasting before and after the dose is considered acceptable [37]. 
However, when it is recommended that the study drug be given with 
food (as would be in routine clinical practice), or where the dosage form 
is a modified release product, fed state studies need to be carried out 
in addition to the fasting state studies. Studies in the fed state require 
the consumption of a high fat breakfast before dosing. Such a breakfast 
must be designed to provide 950-1000 kilo calories. At least 50% of 
these calories must come from fat, 15-20% from proteins and the rest 
from carbohydrates.
STUDY DESIGN
The study should be designed in such a way that the treatment effect 
(formulation effect) can be distinguished from other effects. To reduce 
variability a cross-over design usually is the first choice. Other designs 
or methods may be chosen in specific situations, but should be fully 
justified in the protocol and study report provided. The allocation of the 
subjects to the treatment sequences should be randomized [38].
Single dose study design and multiple dose study design
Single dose study are recommended for both immediate and modified 
release drug products as they are more sensitive in assessing the active 
ingredient released from drug into circulation. In the rare situation 
where there is a problem of sensitivity of the analytical method to 
measure plasma concentration after single dose administration, follow 
multiple dose studies [39-41]. This study design is difficult to conduct, 
required longer monitoring and less sensitive in detecting differences 
in Cmax. Drug candidates for multiple dose studies are drugs with long 
elimination half-life, toxic drugs that requires multiple dose therapy, 
some modified release drugs.
2 × 2 randomized single dose cross-over design
Each subject is randomly assigned to either sequence RT or TR (T-Test, 
R-Reference) at two dosing periods shown in Fig. 5. Dosing periods are 
Fig. 5: Representation of 2×2 randomized single dose cross-over 
design
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separated by a washout period of sufficient length for the drug received 
in the first period to be completely metabolized or excreted from the 
circulation [42-45]. This design is not suitable for drugs with longer 
half-life.
Parallel study design [44,46-48]
Normally wash out period should not exceed 3-4 weeks. If larger 
washout period is necessary a parallel design described in Fig. 6 is 
appropriate. Therefore parallel design is employed for drugs with 
longer half-life, but main drawback of this design is inter subject 
variability cannot be minimized.
Latin square study design
Latin square study design is conducted when there are more than two 
formulations. An experiment involving n treatments, n2 experimental 
units are assigned into n × n square (Fig. 7) in which the rows are 
called row blocks and columns are called column blocks [8]. The design 
minimizes inter-subject variability, carry-over effects, requires less 
number of subjects to get meaning full results. Requires longer time to 
complete the study (washout period exists between study periods) is 
the major drawback in this study design.
Balance incomplete block design (BIBD)
Latin square design will not be ethically advisable when there are 
more than three formulations as each volunteer may require drawing 
of too many blood samples. We can follow BIBD, which is shown in 
Table 1.
Salient features of this design are [44]:
•	 Each	subject	receives	not	more	than	two	formulations
•	 Each	formulation	is	administered	the	same	number	of	times
•	 Each	pair	of	 formulation	occurs	 together	 in	 the	same	number	of	
subjects.
Non-replicate study designs and replicate study design
Non-replicate study designs are recommended for BE studies of most 
orally administered, immediate-release and modified-release dosage 
forms [49]. When the drugs are highly variable, replicate study design 
is preferred (Fig. 8). It allows comparisons of within subject variances, 
reduce the number of subjects needed. Four period, two sequence, two 
formulation design is recommended for replicate study design, where 
there are three period, three sequence, single dose, the study is partially 
replicated [49,50].
PHARMCOKINETIC PARAMETERS [35,51-53]
For single dose studies
In a single dose BE study the following pharmacokinetic parameters 
(Fig. 9) are examined:
•	 AUC0→t	=	Area	under	the	curve	(from	time	0	to	time	of	last	quantifiable	
concentration)
•	 Cmax = Maximum concentration
•	 Tmax = Time to maximum concentration
•	 λz = Terminal elimination rate constant
•	 t½ = Terminal elimination half-life.
A sufficient number of blood samples should be taken to cover at least 
80% of the AUC.
Table 1: Representation of balance incomplete block design













Fig. 6: Representation of parallel study design
Fig. 7: Representation of Latin square design
Fig. 8: Representation of replicate study design
Fig. 9: A typical plasma concentration - time profile showing 
pharmacokinetic parameters after oral administration of single 
dose of a drug
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For multiple dose studies
In multiple dose studies the following pharmacokinetic parameters are 
involved (Fig. 10).
•	 AUC0→Tss	= Area under the curve (from time 0 to dosing interval) at 
steady-state
•	 C	maxss = Maximum concentration at steady state
•	 C	minss = Minimum concentration at steady state
•	 C	avgss = Average concentration at steady state
•	 T	maxss = Time to maximum concentration at steady state
•	 Percentage	fluctuation	=	100	(Cmaxss-Cminss)/C avgss.
Cmax, Cmaxss, Cminss, Tmax, Tmaxss are determined directly from the observed 
data. AUCs are estimated by the conventional trapezoidal rule. In 
multiple dose study, at least three consecutive Cminss should be measured 
to assure attainment of steady state.
STATISTICAL EVALUATION [8,54-57]
Analysis of Variance has been used to analyze C max and AUC. Natural log 
transformation of C max and AUC is performed. Geometric mean of C max 
of test (Cmax ’t) and reference (Cmax ’r) is calculated. Geometric mean ratio 
of test and reference is calculated respectively. Similarly, geometric 
mean ratio of AUC is calculated. This ratio of geometric means is called 
point estimate. 90% confidence interval has to be calculated around the 
ratio of geometric means obtained for AUC and C max. For Cmax and AUC0-t 
the 90% confidence interval for the ratio of test and reference products 
should be contained within the acceptance interval of 80.00-125%. 
Products with a narrow therapeutic index the acceptance interval for 
AUC and Cmax should be tightened to 90.00-111.11%.
CONCLUSION
BA studies helps to produce safe and effective drug product by 
minimizing errors. BE studies reduce the time and cost of the experiment 
by reducing repetitive trails. Appropriate study design must be selected 
that suit the experiment to get meaningful results without violating the 
ethical guidelines.
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